[The effect of glucose-6-phosphate dehydrogenase deficiency on allogeneic hematopoietic stem cell transplantation in...

Area of Science:

• Hematology
• Immunology
• Genetics

Context:

• Allogeneic stem cell hematopoietic transplantation (allo-HSCT) is a critical treatment for hematologic malignancies and other blood disorders.
• Glucose-6-phosphate-dehydrogenase (G6PD) deficiency is a common inherited condition that can affect red blood cell metabolism.
• The impact of G6PD deficiency on allo-HSCT outcomes has not been extensively studied.

Purpose:

• To evaluate the effect of G6PD deficiency on complications and prognosis in patients undergoing allo-HSCT.
• To compare outcomes between G6PD-deficient patients and a matched control group.
• To identify specific risks associated with G6PD deficiency post-transplantation.

Summary:

• A retrospective case-control study compared 7 G6PD-deficient patients with 35 non-deficient patients undergoing allo-HSCT.
• G6PD-deficient patients showed higher incidences of secondary poor graft function (42.9% vs. 8.6%), CMV infection (71.4% vs. 31.4%), and hemorrhagic cystitis (57.1% vs. 8.6%).
• Neutrophil engraftment was successful in all G6PD-deficient patients, but increased vigilance is needed for viral infections and graft complications.

Impact:

• G6PD deficiency does not preclude successful allo-HSCT with conventional regimens.
• Patients with G6PD deficiency require closer monitoring for specific post-transplant complications, including viral infections, hemorrhagic cystitis, and secondary poor graft function.
• These findings inform clinical management strategies for G6PD-deficient patients undergoing allo-HSCT, potentially improving patient outcomes.